H3N2 Infection - Pipeline Review, H1 2015
25 Mar 2015
First in ClassVaccine
Recently added to the BioPortfolio report store,
H3N2 Infection - Pipeline Review, H1 2015 is a new report from
Global Markets Direct published on 2015-02-23.
This 62-page report
is available in PDF
from $2000.
H3N2 Infection - Pipeline Review, H1 2015
Summary
Global Markets Direct’s, ‘H3N2 Infection - Pipeline Review, H1 2015’, provides an overview of the H3N2 Infection’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for H3N2 Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H3N2 Infection and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of H3N2 Infection
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for H3N2 Infection and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the H3N2 Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the H3N2 Infection pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of…
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
H3N2 Infection Overview 7
Therapeutics Development 8
Pipeline Products for H3N2 Infection - Overview 8
Pipeline Products for H3N2 Infection - Comparative Analysis 9
H3N2 Infection - Therapeutics under Development by Companies 10
H3N2 Infection - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
H3N2 Infection - Products under Development by Companies 14
H3N2 Infection - Companies Involved in Therapeutics Development 15
AlphaVax, Inc. 15
Colby Pharmaceutical Company 16
Crucell N.V. 17
Cure Lab, Inc. 18
Inovio Pharmaceuticals, Inc. 19
Johnson & Johnson 20
NanoViricides, Inc. 21
REPLICor Inc. 22
Takeda Pharmaceutical Company Limited 23
Vaxart, Inc. 24
H3N2 Infection - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Combination Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
Aspidasept - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
AVX-502 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
bordetella pertussis [strain BPZE1] vaccine - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
C-05 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
CLVax-1.0 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
CR-9114 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Gamma-Flu - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
ID-38 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
influenza [H3N2] vaccine - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
influenza vaccine - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
JVRS-100 + influenza [H1N1/H3N2] vaccine - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
NVINF-1 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
NVINF-2 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
REP-9 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
seasonal influenza [H3N2] vaccine - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
VX-787 …
For more information open H3N2 Infection - Pipeline Review, H1 2015.
SKU: GMDHC6284IDB
Organizations
Indications
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.